Two of this week's leading stories on Optician were linked to diabetes-related vision loss. Just as MPs were arguing for the Department for Transport to relax driving laws for people with insulin-dependent diabetes, the NHS was recommended not to prescribe Lucentis to treat Diabetic Macular Oedema (DMO).
Lucentis (ranibizumab) was deemed non cost-effective by both The National Institute for Health and Clinical Excellence (NICE) and The Scottish Medicines Consortium (SMC). Diabetes UK reacted by saying people would needlessly lose their sight as a result of the decision, which is not yet finalised.
An alternative to laser treatment, ranibizumab costs
Register now to continue reading
Thank you for visiting Optician Online. Register now to access up to 10 news and opinion articles a month.
Register
Already have an account? Sign in here